Bluebird Bio Enters Medicaid Outcomes-based Agreement For LYFGENIA

bluebird bio, Inc. (BLUE) has signed first Medicaid outcomes-based agreement for LYFGENIA with the state of Michigan. LYFGENIA is a one-time gene therapy approved for the treatment of patients 12 years of age and older with sickle cell disease and a history of vaso-occlusive events.

Related Keywords

Shanghai ,China ,Jingan ,Fujian ,Melinda Gates ,Sam Altman ,Us Department Of Agriculture Food Safety ,Inspection Service ,Apple Inc ,Jen Breakfast Burritos ,Apple Jingan ,Officer Sam Altman ,Special Committee ,Sue Desmond Hellmann ,Washington Based Jen ,Breakfast Burritos ,Food Safety ,Bluebird Bio ,